Table 5.
Validation set and optimized nanoemulsion
| A | B | C | D | Particle size | PDI | Zeta potential mV | Residual standard error (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Actual | Predicted | ||||||||
| Validation | |||||||||
| V1 | 3.00 | 0.04 | 16.46 | 80.50 | 155.60±0.04 | 153.44 | 0.101 | – | 1.41 |
| V2 | 3.00 | 0.04 | 15.46 | 81.50 | 148.40±0.03 | 146.66 | 0.176 | – | 1.19 |
| V3 | 3.00 | 0.04 | 15.96 | 81.00 | 153.90±0.30 | 158.21 | 0.254 | – | 2.72 |
| V4 | 2.90 | 0.03 | 17.00 | 80.07 | 150.00±0.10 | 151.89 | 0.169 | – | 1.24 |
| V5 | 2.90 | 0.03 | 17.50 | 79.57 | 152.30±0.18 | 154.19 | 0.042 | – | 1.23 |
| Optimization | |||||||||
| 3.00 | 0.04 | 15.00 | 81.96 | 141.57±0.05 | 143.54 | 0.168 | −37.10 | 1.37 | |
Abbreviations: A, Gemcitabine; B, NaCl solution; C, Tween 80 and Span 80 (at ratio 3:7); D, medium chain triglycerides.